Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN004 in Patients With Solid Tumors
NCT02391727Phase 1Completed
- Sponsor
- Xingmeng Biopharmaceutical
- Start
- May 2015
- Primary completion
- Oct 2018
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of ribaxamase in solid tumor, colorectal cancer (CRC), head and neck cancer (HNC) and 2 more (3 arms), sponsored by Xingmeng Biopharmaceutical. Primary endpoint: Number of patients with adverse events. Started May 2015; status: completed.
02
Drugs
ribaxamase
03
Conditions
solid tumorcolorectal cancer (CRC)head and neck cancer (HNC)non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT02391727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02391727.